

Format for disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Part A- Details of shareholding

1. Name of the Target Company	Krebs Biochemicals & Industries Limited		
2. Names of the Stock Exchanges where the shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited		
3. Particulars of the shareholder(s): a. Name of the person(s) together with Persons Acting in Concert (PAC) whose total (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. Or b. Name(s) of the promoter(s), member of the promoter group and PAC with him	1. Dr R T Ravi 2. Mr. Avinash Ravi 3. Mrs. Hemalata Ravi 4. Mr. Aditya Ravi 5. Mr. Ajay Ravi		
4. Particulars of the shareholding of the person(s) mentioned at (3) above	Number of shares	% w.r.t total share/voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on 31 st March, 2019 , holding of			
a) Shares	4978230	29.93%	29.93 %
b) Voting rights (otherwise than by shares)	Nil	0.00%	0.00%
c) Warrants	Nil	0.00%	0.00%
d) Convertible Securities	Nil	0.00%	0.00%
e) Any other instrument that would entitle the holder to receive shares in the TC.	Nil	0.00%	0.00%
Total	4978230	29.93%	29.93%



Name of the Target Company: Krebs Biochemicals & Industries Limited

Names of the person and Person Acting in Concert (PAC) with the person	Whether the person belongs to the promoter/promoter group	No. Of shares
Dr R T Ravi	Promoter	23474
Mr. Avinash Ravi	Promoter	2140272
Mrs. Hemalata Ravi	Promoter	2691524
Mr. Aditva Ravi	Promoter	10672
Mr. Ajay Ravi	Promoter	112288

Authorised Representative of promoter group

Place: Hyderabad

Date: 05-04-2019

Note: In case of Promoter(s) making disclosure under Regulation 30(2), no additional disclosure under Regulation 30(1) is required.

(*)Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.